Chris is the Chairman of Schofield Sweeney. He advises on corporate matters and regularly advises…View Profile View all
Manchester-based drug discovery and development company C4X Discovery has raised £5m through a share placing as it seeks to progress its existing "innovative pipeline towards the clinic".
The AIM-listed business has placed 4.9 million shares with current and new investors at a placing price of 102p each.
The cash raised will be used to further its pre-clinical pipeline towards clinical development and invest in developing new lead compounds.
Chief executive Clive Dix said: "The completion of this fundraise will allow C4XD to continue on its path to becoming the world's most productive drug discovery engine.
"We are already exploiting cutting edge-technologies to design and create best-in-class small molecule candidates."
C4X Discovery was advised by Schofield Sweeney’s Chris Schofield, Chris Blantern and Jessica Fielden.